Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DeuterOncology NV logo — Developing deuterated BEST in CLASS MET kinase Inhibitor

DeuterOncology NV

Developing deuterated BEST in CLASS MET kinase Inhibitor

Founded 2020 Belgium Belgium 5 employees Series A Total: $5.65M Biotechnology

General Information

Company Name DeuterOncology NV
Founded Year 2020
Location Belgium Belgium +1
Employees 5
Industries Biotechnology
Funding Stage Series A
Social

Get notified when DeuterOncology NV moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About DeuterOncology NV

DeuterOncology is a biotechnology startup based in Liege, Belgium, founded in 2020 with the aim of developing deuterated BEST in CLASS MET kinase Inhibitor. The company, led by Dr. Timothy Perera, is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2.

The company recently secured a significant €5.65M Series A investment on 19 January 2023, with participation from notable investors including Newton BioCapital, Noshaq, and INVESTSUD.

DeuterOncology's innovative approach in the biotechnology industry, coupled with its strong investor backing, positions the company as a promising player in the field of developing advanced kinase inhibitors for the treatment of cancer. With its focus on pioneering solutions and strategic partnerships, DeuterOncology is poised for further growth and impact in the biotechnology sector.

Taxonomy: Deuterated, MET kinase inhibitor, Clinical stage, Brain penetrant, Cancer therapy, Targeted therapy, Drug development, Small molecules, Preclinical stage, RAS pathway inhibitor, Clinical development, Biotech company, Timothy Perera, Liege based

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor Investor Investor
19 Jan 2023
Seed Round •••••• 1
Investor
24 Feb 2021

DeuterOncology NV Alternatives & Competitors

DeuterOncology NV vs
iOnctura
iOnctura Switzerland

Developing precision small molecules to combat hard-to-treat tumors.

Series B
28 employees
Biotechnology, Health Care
DeuterOncology NV vs
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. United States

The Path to Better

Series B
14 employees
Biotechnology, Health Care
DeuterOncology NV vs
NewAmsterdam Pharma Corporation
NewAmsterdam Pharma Corporation United States

NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiom...

IPO
102 employees
Biotechnology, Life Sciences

FAQ About DeuterOncology NV

Developing deuterated BEST in CLASS MET kinase Inhibitor
DeuterOncology NV was founded in 2020.
DeuterOncology NV is headquartered in Belgium.
DeuterOncology NV operates in the following industries: Biotechnology.
DeuterOncology NV has approximately 5 employees.
DeuterOncology NV has completed 2 funding rounds, raising a total of $5.65M. The latest funding stage is Series A.
Top alternatives and competitors to DeuterOncology NV include iOnctura, Treadwell Therapeutics, Inc., NewAmsterdam Pharma Corporation, MEI Pharma, Crystalys Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DeuterOncology NV and iOnctura are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors DeuterOncology NV and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy